The Insulin Revolution in Israel: One Injection a Week Instead of Daily Treatment

The weekly insulin Awiqli has arrived in Israel, reducing basal injections from 365 to 52 per year. The Association of Diabetes Specialist Nurses warns of dosing errors that could cause life-threatening hypoglycemia. The drug is intended for type 2 diabetes and type 1 diabetes in combination with rapid-acting insulin.

The first weekly insulin in Israel, Awiqli, has arrived and may reduce the number of basal insulin injections from 365 to 52 per year. The drug, developed by Novo Nordisk, was approved in the European Union in May 2024 and registered in Israel in August 2025. Alongside the good news, the Association of Diabetes Specialist Nurses (AMLY) warns of dosing errors that could cause life-threatening hypoglycemia. Sima Arbely, CEO of AMLY, explains that the transition from daily to weekly treatment requires precise dose adjustment, as each weekly injection contains a concentrated dose seven times higher than the daily dose. The drug is intended for adults with type 2 diabetes, and for type 1 diabetes in combination with rapid-acting insulin. Clinical trials found an increased risk of hypoglycemia in type 1 diabetes. The organization emphasizes that the new pen does not replace human and professional guidance.